Search research articles
Contact Us
Filters
Showing results (1-10 of 68) with videos related to
Page
of 7
Sort By:
Molecular Oncology
|
January 6, 2015
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
Daniel V T Catenacci
JCO Precision Oncology
|
April 19, 2019
When Inhibitor MET Biomarker: Postmortem or Initium Novum?
Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2021
A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer
Daniel V T Catenacci
The Lancet. Oncology
|
September 7, 2015
Expansion platform type II: testing a treatment strategy
Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2021
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA
Daniel V T Catenacci
Discovery Medicine
|
September 4, 2013
Gastroesophageal cancer: focus on epidemiology, classification, and staging
Amikar Sehdev, Daniel V T Catenacci
Journal of Hematology & Oncology
|
September 10, 2013
Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
Amikar Sehdev, Daniel V T Catenacci
Archives of Pathology & Laboratory Medicine
|
August 29, 2014
Next-generation companion diagnostics: promises, challenges, and solutions
Joseph D Khoury, Daniel V T Catenacci
Surgical Oncology Clinics of North America
|
March 11, 2017
Novel Targeted Therapies for Esophagogastric Cancer
Steven B Maron, Daniel V T Catenacci
Blood Reviews
|
May 12, 2005
Myelodysplasic syndromes: a comprehensive review
Daniel V T Catenacci, Gary J Schiller
Page
of 7
Search research articles
Search
Showing results (1-10 of 68) with videos related to
Sort By:
Page
of 7
Molecular Oncology
|
January 6, 2015
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
Daniel V T Catenacci
JCO Precision Oncology
|
April 19, 2019
When Inhibitor MET Biomarker: Postmortem or Initium Novum?
Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2021
A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer
Daniel V T Catenacci
The Lancet. Oncology
|
September 7, 2015
Expansion platform type II: testing a treatment strategy
Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2021
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA
Daniel V T Catenacci
Discovery Medicine
|
September 4, 2013
Gastroesophageal cancer: focus on epidemiology, classification, and staging
Amikar Sehdev, Daniel V T Catenacci
Journal of Hematology & Oncology
|
September 10, 2013
Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
Amikar Sehdev, Daniel V T Catenacci
Archives of Pathology & Laboratory Medicine
|
August 29, 2014
Next-generation companion diagnostics: promises, challenges, and solutions
Joseph D Khoury, Daniel V T Catenacci
Surgical Oncology Clinics of North America
|
March 11, 2017
Novel Targeted Therapies for Esophagogastric Cancer
Steven B Maron, Daniel V T Catenacci
Blood Reviews
|
May 12, 2005
Myelodysplasic syndromes: a comprehensive review
Daniel V T Catenacci, Gary J Schiller
Page
of 7